SIGMAR1 and Alzheimer disease: Donepezil, which has Sigma1R agonist and noncovalent reversible inhibitor of acetylcholinesterase (AChE) properties [360,361], is undergoing phase 3 clinical trials designed to evaluate the drug’s effect on AD symptoms after 6 months of treatment (NCT04661280).